BMY

Bristol-Myers Squibb Company

BMY, USA

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

https://www.bms.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

Quarterly

Rate:

0.63

Next Payout:

Feb 2, 2026

Yield:

4.6116 %
BMY
stock
BMY

Leerink bullish on Bristol-Myers Squibb Company (BMY) amid ample pipeline optionality in 2026 MSN

Read more →
BMY
stock
BMY

Bristol-Myers Squibb Company's (NYSE:BMY) recent 3.0% pullback adds to one-year year losses, institutional owners may take drastic measures Yahoo Finance

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$56.9565

Analyst Picks

Strong Buy

4

Buy

4

Hold

18

Sell

0

Strong Sell

1

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

High

18.61

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

6.00

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Low

11.86 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

2.27 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

49.02 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

4.22

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 73.30% of the total shares of Bristol-Myers Squibb Company

1.

Vanguard Group Inc

(9.5766%)

since

2025/06/30

2.

BlackRock Inc

(8.4614%)

since

2025/06/30

3.

JPMorgan Chase & Co

(5.1075%)

since

2025/06/30

4.

State Street Corp

(4.6545%)

since

2025/06/30

5.

Charles Schwab Investment Management Inc

(3.4785%)

since

2025/06/30

6.

Capital Research & Mgmt Co - Division 3

(3.2505%)

since

2025/06/30

7.

Vanguard Total Stock Mkt Idx Inv

(3.143%)

since

2025/07/31

8.

Schwab US Dividend Equity ETFâ„¢

(2.7874%)

since

2025/08/30

9.

Vanguard 500 Index Investor

(2.4749%)

since

2025/07/31

10.

Geode Capital Management, LLC

(2.2686%)

since

2025/06/30

11.

NORGES BANK

(1.6495%)

since

2025/06/30

12.

Ameriprise Financial Inc

(1.6006%)

since

2025/06/30

13.

Morgan Stanley - Brokerage Accounts

(1.317%)

since

2025/06/30

14.

Wellington Management Company LLP

(1.2687%)

since

2025/06/30

15.

Fidelity 500 Index

(1.2674%)

since

2025/07/31

16.

UBS Asset Mgmt Americas Inc

(1.2385%)

since

2025/06/30

17.

Northern Trust Corp

(1.2223%)

since

2025/06/30

18.

SPDR® S&P 500® ETF

(1.2066%)

since

2025/08/31

19.

iShares Core S&P 500 ETF

(1.2031%)

since

2025/08/31

20.

PRIMECAP Management Company

(1.1273%)

since

2025/06/30

21.

Independent Franchise Partners LLP

(1.0306%)

since

2025/06/30

22.

Bank of New York Mellon Corp

(1.0249%)

since

2025/06/30

23.

Capital Group American Mutual Comp

(0.9648%)

since

2025/06/30

24.

American Funds American Mutual A

(0.9648%)

since

2025/06/30

25.

Amvescap Plc.

(0.8998%)

since

2025/06/30

26.

Vanguard Value Index Inv

(0.8861%)

since

2025/07/31

27.

Bank of America Corp

(0.8794%)

since

2025/06/30

28.

Vanguard Health Care Inv

(0.8474%)

since

2025/06/30

29.

Dimensional Fund Advisors, Inc.

(0.7993%)

since

2025/06/30

30.

FMR Inc

(0.7973%)

since

2025/06/30

31.

The Health Care Select Sector SPDR® ETF

(0.6827%)

since

2025/08/31

32.

Capital Group Fundamental Invtrs Comp

(0.6465%)

since

2025/06/30

33.

American Funds Fundamental Invs A

(0.6465%)

since

2025/06/30

34.

Vanguard PRIMECAP Inv

(0.6184%)

since

2025/06/30

35.

Vanguard Institutional Index I

(0.6044%)

since

2025/07/31

36.

JPM US Equity Income-Composite

(0.5644%)

since

2025/06/30

37.

JPMorgan Equity Premium Income ETF

(0.5483%)

since

2025/08/29

38.

American Funds American Balanced A

(0.5407%)

since

2025/06/30

39.

State St S&P 500® Indx SL Cl III

(0.5337%)

since

2025/08/31

40.

JPMorgan Equity Income I

(0.5192%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

1.63

Latest Release

Date

2025-09-30

EPS Actual

1.63

EPS Estimate

1.69

EPS Difference

-0.06

Surprise Percent

-3.5503%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Highly Defensive(7)
Dividend
Decent Dividend Payer(4)
Economic Moat
Wide Moat Company(8.3)
GARP
Fair GARP(5.5)
Growth
Moderate Growth(5)
Momentum
Moderate Momentum(4.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
High Quality(7)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.